Talk:Bromazolam: Difference between revisions

(11 intermediate revisions by 4 users not shown)

Line 1:

{{decree|type=notice|message=This article is currently in the 'Talk' namespace as an unfinished draft. This section is used to host drafts for unpublished articles and discussions of published ones. If you wish to discuss or suggest improvements to this draft, please do so in the 'Discussion' section at the bottom of the page. This notice will be removed once the draft has been approved for publication by an administrator.}}{{headerpanel|{{Approval}}}}

~~Dosages and duration of action reported by the most reliable and up-to-date resources:~~

~~- Light dose: 0.5 mg - 1 mg~~

~~- Common dose: 1 mg - 2 mg~~

~~- Strong/heavy dose: 2 mg - 4 mg+~~

~~- Onset of effects (oral): 15–45 min~~

~~- Duration of action: 5–8 hours~~

~~(Source: WHO Critical Review findings <ref>[https://cdn.who.int/media/docs/default-source/controlled-substances/45th-ecdd/bromazolam_draft.pdf WHO Critical Review Report: Bromazolam (2022)]~~</~~ref~~>)

{{headerpanel|{{DepressantOD|benzodiazepines}}}}

Line 23:

Line 15:

The [[benzodiazepine#Discontinuation|sudden discontinuation of benzodiazepines]] after prolonged use can lead to severe withdrawal symptoms, including seizures or death.<ref>A fatal case of benzodiazepine withdrawal. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/19465812</ref> Users are strongly advised to [[taper]] their dosage gradually rather than stopping abruptly.<ref>Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain - Appendix B-6: Benzodiazepine Tapering | http://nationalpaincentre.mcmaster.ca/opioid/cgop_b_app_b06.html</ref>

~~For guidelines on properly formatting a substance article, refer to the [[Content Style Guide - Substance]] document.~~

==History and Culture==

Line 39:

Line 29:

The GABAA receptor consists of five subunits out of a possible 19, leading to a wide variety of receptor subtypes with different properties and interactions with benzodiazepines. Triazolobenzodiazepines like Bromazolam may also possess antidepressant properties, potentially due to their chemical similarity to tricyclic antidepressants.<ref>Barbee JG (October 1993). "Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives". ''The Journal of Clinical Psychiatry''. 54 Suppl (Suppl): 86–97, discussion 98–101. <nowiki>PMID 8262893</nowiki>.</ref>

==Half Life==

4-8 hours with after effects being reported into the next 12 hours. In some cases people have reported feeling anxiolytic effects well into the 24+ hour mark and withdrawals/rebound anxiety not starting until Day 4/5.

==Subjective Effects==

Line 63:

Line 56:

* '''[[Effect::Visual acuity suppression]]'''

* '''[[Effect::Blurred ~~Vision~~]]'''

* '''[[Effect::Blurred vision]]'''

* '''[[Effect::Double vision]]

}}

Line 100:

Line 94:

Additional experience reports for Bromazolam can be found here:

* [https://www.erowid.org/experiences/subs/exp_Bromazolam_Retrospective_I_Summary.shtml Erowid Experience Vaults: Bromazolam]

*[https://www.erowid.org/experiences/subs/exp_Bromazolam_Retrospective_I_Summary.shtml Erowid Experience Vaults: Bromazolam]

==Toxicity and Harm Potential==

{{toxicity|Dosage=0.5-1 mg - Light 1 mg-3 mg - Moderate 3 mg-5 mg+ - Strong}}

It is strongly recommended to employ [[responsible use|harm reduction practices]] while using this substance.

Research on the toxicity of Bromazolam has not been done, however there large amounts of overdoses have been reported in relation to Bromazolam. It is strongly recommended to employ [[responsible use|harm reduction practices]] while using this or any substance.

===Tolerance and Addiction Potential===

Long-term use of Bromazolam can lead to tolerance, physical dependence, and withdrawal symptoms associated with benzodiazepines, including the potential for life-threatening withdrawal seizures.

Long-term use of Bromazolam can lead to tolerance, physical dependence, and withdrawal symptoms associated with benzodiazepines, including the potential for life-threatening withdrawal seizures. Notably, tolerance to Bromazolam builds more quickly than with other benzodiazepines, increasing the risk of dependence.

===Dangerous Interactions===

Line 114:

Line 109:

==Legal Status==

Line 124:

Line 121:

==See Also==

* [[Responsible use]]

*[[Responsible use]]

==External Links==

* [https://en.wikipedia.org/wiki/Bromazolam Bromazolam (Wikipedia)]

* [https://www.erowid.org/experiences/subs/exp_Bromazolam.shtml Bromazolam (Erowid Vault)]

*[https://en.wikipedia.org/wiki/Bromazolam Bromazolam (Wikipedia)]

* [https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=3065 Bromazolam (Isomer Design)]

*[https://www.erowid.org/experiences/subs/exp_Bromazolam.shtml Bromazolam (Erowid Vault)]

* [https://cdn.who.int/media/docs/default-source/46th-ecdd/bromazolam_46th-ecdd-critical-review_public-version.pdf?sfvrsn=4f1bccfa_1 WHO Critical Report October 2023]

*[https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=3065 Bromazolam (Isomer Design)]

*[https://cdn.who.int/media/docs/default-source/46th-ecdd/bromazolam_46th-ecdd-critical-review_public-version.pdf?sfvrsn=4f1bccfa_1 WHO Critical Report October 2023]

==Literature==

* APA formatted references

*APA formatted references

Refer to the [[citation formatting guide]] for help in properly formatting citations.

@@ Line 1: / Line 1: @@
 {{decree|type=notice|message=This article is currently in the 'Talk' namespace as an unfinished draft. This section is used to host drafts for unpublished articles and discussions of published ones. If you wish to discuss or suggest improvements to this draft, please do so in the 'Discussion' section at the bottom of the page. This notice will be removed once the draft has been approved for publication by an administrator.}}{{headerpanel|{{Approval}}}}
-Dosages and duration of action reported by the most reliable and up-to-date resources:
+<br />
-- Light dose: 0.5 mg - 1 mg
-- Common dose: 1 mg - 2 mg
-- Strong/heavy dose: 2 mg - 4 mg+
-- Onset of effects (oral): 15–45 min
-- Duration of action: 5–8 hours
-(Source: WHO Critical Review findings <ref>[https://cdn.who.int/media/docs/default-source/controlled-substances/45th-ecdd/bromazolam_draft.pdf WHO Critical Review Report: Bromazolam (2022)]</ref>)
 {{headerpanel|{{DepressantOD|benzodiazepines}}}}
@@ Line 23: / Line 15: @@
 The [[benzodiazepine#Discontinuation|sudden discontinuation of benzodiazepines]] after prolonged use can lead to severe withdrawal symptoms, including seizures or death.<ref>A fatal case of benzodiazepine withdrawal. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/19465812</ref> Users are strongly advised to [[taper]] their dosage gradually rather than stopping abruptly.<ref>Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain - Appendix B-6: Benzodiazepine Tapering | http://nationalpaincentre.mcmaster.ca/opioid/cgop_b_app_b06.html</ref>
-For guidelines on properly formatting a substance article, refer to the [[Content Style Guide - Substance]] document.
 ==History and Culture==
@@ Line 39: / Line 29: @@
 The GABA<sub>A</sub> receptor consists of five subunits out of a possible 19, leading to a wide variety of receptor subtypes with different properties and interactions with benzodiazepines. Triazolobenzodiazepines like Bromazolam may also possess antidepressant properties, potentially due to their chemical similarity to tricyclic antidepressants.<ref>Barbee JG (October 1993). "Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives". ''The Journal of Clinical Psychiatry''. 54 Suppl (Suppl): 86–97, discussion 98–101. <nowiki>PMID 8262893</nowiki>.</ref>
+==Half Life==
+-8 hours with after effects being reported into the next 12 hours. In some cases people have reported feeling anxiolytic effects well into the 24+ hour mark and withdrawals/rebound anxiety not starting until Day 4/5.
 ==Subjective Effects==
@@ Line 63: / Line 56: @@
 * '''[[Effect::Visual acuity suppression]]'''
-* '''[[Effect::Blurred Vision]]'''
+* '''[[Effect::Blurred vision]]'''
+* '''[[Effect::Double vision]]
 }}
@@ Line 100: / Line 94: @@
 Additional experience reports for Bromazolam can be found here:
-* [https://www.erowid.org/experiences/subs/exp_Bromazolam_Retrospective_I_Summary.shtml Erowid Experience Vaults: Bromazolam]
+*[https://www.erowid.org/experiences/subs/exp_Bromazolam_Retrospective_I_Summary.shtml Erowid Experience Vaults: Bromazolam]
 ==Toxicity and Harm Potential==
 {{toxicity|Dosage=0.5-1 mg - Light<br> 1 mg-3 mg - Moderate<br> 3 mg-5 mg+ - Strong}}
-It is strongly recommended to employ [[responsible use|harm reduction practices]] while using this substance.
+Research on the toxicity of Bromazolam has not been done, however there large amounts of overdoses have been reported in relation to Bromazolam. It is strongly recommended to employ [[responsible use|harm reduction practices]] while using this or any substance.
 ===Tolerance and Addiction Potential===
-Long-term use of Bromazolam can lead to tolerance, physical dependence, and withdrawal symptoms associated with benzodiazepines, including the potential for life-threatening withdrawal seizures.
+Long-term use of Bromazolam can lead to tolerance, physical dependence, and withdrawal symptoms associated with benzodiazepines, including the potential for life-threatening withdrawal seizures. Notably, tolerance to Bromazolam builds more quickly than with other benzodiazepines, increasing the risk of dependence.
 ===Dangerous Interactions===
@@ Line 114: / Line 109: @@
 {{DangerousInteractions}}
 {{DangerousInteractions/Intro}}
+{{DangerousInteractions/Depressants}}
 ==Legal Status==
@@ Line 124: / Line 121: @@
 ==See Also==
-* [[Responsible use]]
+*[[Responsible use]]
 ==External Links==
-* [https://en.wikipedia.org/wiki/Bromazolam Bromazolam (Wikipedia)]
-* [https://www.erowid.org/experiences/subs/exp_Bromazolam.shtml Bromazolam (Erowid Vault)]
+*[https://en.wikipedia.org/wiki/Bromazolam Bromazolam (Wikipedia)]
-* [https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=3065 Bromazolam (Isomer Design)]
+*[https://www.erowid.org/experiences/subs/exp_Bromazolam.shtml Bromazolam (Erowid Vault)]
-* [https://cdn.who.int/media/docs/default-source/46th-ecdd/bromazolam_46th-ecdd-critical-review_public-version.pdf?sfvrsn=4f1bccfa_1 WHO Critical Report October 2023]
+*[https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=3065 Bromazolam (Isomer Design)]
+*[https://cdn.who.int/media/docs/default-source/46th-ecdd/bromazolam_46th-ecdd-critical-review_public-version.pdf?sfvrsn=4f1bccfa_1 WHO Critical Report October 2023]
 ==Literature==
-* APA formatted references
+*APA formatted references
 Refer to the [[citation formatting guide]] for help in properly formatting citations.